Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report Evaluates Growth Drivers, Challenges And Market Dynamics

The field of RNA-based oncolytic therapies is gaining rapid traction as innovative cancer treatments continue to evolve. Fueled by scientific breakthroughs and increasing investment, this sector is set to experience significant expansion over the coming years. Let's explore the current market size, key players, emerging trends, and segmentation within this promising field.

Projected Growth and Size of the RNA-Based Oncolytic Therapy Market
The RNA-based oncolytic therapy market has witnessed impressive growth recently and is poised to expand further. Market value is expected to rise from $2.12 billion in 2025 to $2.51 billion in 2026, representing a compound annual growth rate (CAGR) of 18.7%. This surge during the historical period is largely driven by advancements in cancer virology research, enhanced understanding of tumor immunology, the availability of clinical trial frameworks, increased funding in oncology research, and the early successes seen in oncolytic virus studies.

Download a free sample of the ribonucleic acid (rna)-based oncolytic therapy market report:
https://thebusinessresearchcompany.com/sample_request?id=89190689&type=smp&name=Ribonucleic%20Acid%20%28RNA%29-Based%20Oncolytic%20Therapy%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Outlook for the RNA-Based Oncolytic Therapy Market Through 2030
Looking ahead, the market for RNA-based oncolytic therapies is anticipated to grow even faster, reaching $4.94 billion by 2030 with a CAGR of 18.4%. The forecasted expansion can be attributed to factors such as growing regulatory approvals of RNA-driven cancer treatments, rising demand for personalized oncology approaches, broadening immuno-oncology pipelines, increased investments in gene and cell therapy development, as well as improvements in RNA delivery technologies. Key trends shaping the future include the advancement of RNA virus engineering, wider adoption of combination therapies, heightened focus on immune system activation, development of tumor-specific RNA therapies, and stronger integration of precision oncology tools.

Leading Companies Steering the RNA-Based Oncolytic Therapy Market
Several prominent organizations are at the forefront of this market, including AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., and TransCode Therapeutics Inc.

View the full ribonucleic acid (rna)-based oncolytic therapy market report:
https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-based-oncolytic-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Collaborative Efforts Advancing RNAi-Based Oncolytic Therapy Development
In June 2023, US-based Charles River Laboratories International, Inc., a contract research organization, announced a partnership with South Korea's Curigin Co., Ltd., aimed at advancing RNA interference (RNAi)-based oncolytic gene therapies. This collaboration leverages Charles River's contract development and manufacturing organization (CDMO) expertise to facilitate the development and production of Curigin's RNAi-driven cancer therapies, supporting both preclinical and clinical trials.

Technological Innovations Driving Market Progress in RNA-Based Oncolytic Therapy
Key players in the RNA-based oncolytic therapy sector are heavily investing in synthetic messenger RNA (mRNA) technologies designed to boost tumor-targeting precision, enhance immune activation, and deliver more durable therapeutic outcomes. Synthetic mRNA technology involves producing lab-engineered mRNA sequences that instruct cells to generate specific proteins beneficial for treating diseases such as cancer. For example, in June 2024, China's CSPC Pharmaceutical Group Limited obtained regulatory approval to initiate clinical trials for SYS6020, a synthetic mRNA-based therapy targeting myeloma cancer cells. SYS6020 utilizes mRNA-lipid nanoparticle delivery to selectively eliminate cancer cells while minimizing side effects and shows promise for treating some autoimmune conditions as well.

Market Segmentation Covered in the RNA-Based Oncolytic Therapy Report
This market report categorizes the RNA-based oncolytic therapy market into several important segments, including:
1) Therapy Type:
- Messenger RNA (mRNA)-Based Oncolytic Therapy
- Small Interfering RNA (siRNA)-Based Oncolytic Therapy
- Micro RNA (miRNA)-Based Oncolytic Therapy
- Other Therapy Types
2) Route of Administration:
- Intravenous
- Intratumoral
- Other Routes
3) Application:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Applications
4) End-User:
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- Other End Users

Subsegments include:
- For mRNA-based therapies: Self-amplifying mRNA (saRNA), non-replicating mRNA, circular RNA (circRNA)-based mRNA therapies
- For siRNA-based therapies: Chemically modified siRNA, nanoparticle-delivered siRNA, conjugated siRNA
- For miRNA-based therapies: miRNA mimics, miRNA inhibitors (antagomirs), miRNA sponges or decoys
- Other types: Long non-coding RNA (lncRNA)-based therapies, short hairpin RNA (shRNA)-based therapies, aptamer-RNA-based oncolytic agents

This detailed segmentation provides a comprehensive view of the diverse therapeutic approaches and applications within the RNA-based oncolytic therapy landscape.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.